Table 7 Clinicopathologic characteristics according to triple negative and non-triple negative breast cancer
| Â | Â | No. of Pts | Triple negative (N = 47) | Non-triple negative (N = 98) | p-value* |
|---|---|---|---|---|---|
Variables | Â | Â | No. of Pts (%) | No. of Pts (%) | Â |
Age | < 50 | 102 | 33 (70.2) | 69 (70.4) | 0.981 |
|  | ≥ 50 | 43 | 14 (29.8) | 29 (29.6) |  |
Performance | ECOG 0–1 | 139 | 45 (95.7) | 94 (95.9) | 0.961 |
| Â | ECOG 2 | 6 | 2 (4.3) | 4 (4.1) | Â |
Initial clinical stage | IIA, IIB, IIIA | 93 | 27 (57.4) | 66 (67.3) | 0.245 |
| Â | IIIB, IIIC | 52 | 20 (42.6) | 32 (32.7) | Â |
Inflammatory breast cancer | Yes | 18 | 4 (8.5) | 14 (14.3) | 0.425 |
| Â | No | 127 | 43 (91.5) | 84 (85.7) | Â |
Radiologic response | Responder | 100 | 39 (83.0) | 61 (62.2) | 0.012 |
| Â | Non-responder | 45 | 8 (17.0) | 37 (37.8) | Â |
pCR | No | 134 | 39 (83.0) | 95 (96.9) | 0.005 |
| Â | Yes | 11 | 8 (17.0) | 3 (3.1) | Â |
Adjuvant hormonal therapy | Yes | 63 | 0 (0.0) | 63 (64.3) | <0.001 |
| Â | No | 82 | 47(100.0) | 35 (35.7) | Â |
Radiation therapy | Yes | 128 | 41 (87.2) | 87 (88.8) | 0.787 |
| Â | No | 17 | 6 (12.8) | 11 (11.2) | Â |
Nuclear grade | I, II | 41 | 3 (8.1) | 38 (41.8) | <0.001 |
| Â | III | 87 | 34 (91.9) | 53 (58.2) | Â |
Histologic grade | I, II | 39 | 7 (20.0) | 32 (37.2) | 0.066 |
| Â | III | 82 | 28 (80.0) | 54 (62.8) | Â |
bcl-2 | Positive | 63 | 14 (31.8) | 49 (52.7) | 0.022 |
| Â | Negative | 74 | 30 (68.2) | 44 (47.3) | Â |
Ki-67 | Low expression | 56 | 13 (28.3) | 43 (45.3) | 0.053 |
| Â | High expression | 85 | 33 (71.7) | 52 (54.7) | Â |
p53 | Low expression | 67 | 22 (46.8) | 45 (46.9) | 0.994 |
| Â | High expression | 76 | 25 (53.2) | 51 (53.1) | Â |